PAUL A KNIERY
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine
- Where
- BOWLING GREEN, KY
- NPI
- 1598791071
- Received
- $96,760 in 301 records, 2019 to 2025 ($4,171 general, $92,589 research)
- As principal investigator
- $758,835 of research payments to others in 34 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 10 | $192 |
| 2023 | General payment | 57 | $818 |
| 2023 | Research payment | 2 | $707 |
| 2022 | General payment | 67 | $965 |
| 2022 | Research payment | 3 | $91,882 |
| 2021 | General payment | 55 | $978 |
| 2020 | General payment | 46 | $511 |
| 2019 | General payment | 61 | $704 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 5 | $92,589 |
| Food and Beverage | 296 | $4,171 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-08-13 | SANOFI-AVENTIS U.S. LLC | $28 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-02-29 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-02-22 | Xeris Pharmaceuticals, Inc. | $18 | Food and Beverage | In-kind items and services | GVOKE HYPOPEN Drug, Diabetes | 2024 | |
| 2024-02-19 | Paratek Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | NUZYRA Drug, ANTIBIOTIC | 2024 | |
| 2024-02-13 | SANOFI-AVENTIS U.S. LLC | $20 | Food and Beverage | In-kind items and services | TZIELD Biological, Endocrine & Metabolic Diseases | 2024 | |
| 2024-02-09 | Novo Nordisk Inc | $17 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2024 | |
| 2024-01-30 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2024 | |
| 2024-01-24 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2024-01-10 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2024 | |
| 2024-01-05 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2024 | |
| 2023-12-19 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-12-15 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-12-12 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-12-05 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-12-01 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-11-10 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-11-08 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-11-02 | ABBVIE INC. | $1 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-10-26 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-10-10 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-09-26 | Seqirus USA Inc | $17 | Food and Beverage | In-kind items and services | FLUCELVAX QUADRIVALENT Biological, Vaccines | 2023 | |
| 2023-09-15 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2023 | |
| 2023-09-12 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-09-07 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-31 | PFIZER INC. | $19 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PAIN | 2023 | |
| 2023-08-29 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-08-24 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-08-22 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-08-17 | AstraZeneca Pharmaceuticals LP | $22 | Food and Beverage | In-kind items and services | FLUMIST QUADRIVALENT Biological, Respiratory | 2023 | |
| 2023-08-14 | Corium, LLC | $11 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2023 | |
| 2023-08-09 | KYOWA KIRIN, INC. | $27 | Food and Beverage | In-kind items and services | Crysvita Drug, fibroblast growth factor 23 (FGF23) blocking antibody. | 2023 | |
| 2023-07-27 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-07-24 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-07-21 | IRONWOOD PHARMACEUTICALS, INC | $15 | Food and Beverage | Cash or cash equivalent | Linzess Drug, GI | 2023 | |
| 2023-07-20 | PFIZER INC. | $23 | Food and Beverage | In-kind items and services | XYNTHA Biological, HEMATOLOGY | 2023 | |
| 2023-07-18 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-07-17 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-07-13 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | PAXLOVID Drug, INFECTIOUS DISEASES | 2023 | |
| 2023-06-23 | GlaxoSmithKline, LLC. | $16 | Food and Beverage | In-kind items and services | PEDIARIX Biological, VACCINES | 2023 | |
| 2023-06-19 | Corium, LLC | $12 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2023 | |
| 2023-06-13 | Amgen Inc. | $13 | Food and Beverage | In-kind items and services | Repatha Biological, Cardiology | 2023 | |
| 2023-06-06 | SANOFI PASTEUR INC. | $14 | Food and Beverage | In-kind items and services | VAXELIS Biological, Vaccines | 2023 | |
| 2023-05-30 | IRONSHORE PHARMACEUTICALS INC. | $17 | Food and Beverage | Cash or cash equivalent | JORNAY PM Drug, CENTRAL NERVOUS SYSTEM STIMULANT | 2023 | |
| 2023-05-22 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-05-11 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-05-02 | Supernus Pharmaceuticals, Inc. | $13 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2023 | |
| 2023-05-01 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2023 | |
| 2023-04-17 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-04-11 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-04-10 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2023 | |
| 2023-04-07 | Ultragenyx Pharmaceutical Inc. | $16 | Food and Beverage | In-kind items and services | 2023 | ||
| 2023-04-03 | Eli Lilly and Company | $560 | Research payment | In-kind items and services | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 | |
| 2023-03-28 | IRONSHORE PHARMACEUTICALS INC. | $16 | Food and Beverage | Cash or cash equivalent | JORNAY PM Drug, CENTRAL NERVOUS SYSTEM STIMULANT | 2023 | |
| 2023-03-21 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-03-20 | Corium, LLC | $9 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2023 | |
| 2023-03-14 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-03-10 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-03-01 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-02-27 | IRONSHORE PHARMACEUTICALS INC. | $17 | Food and Beverage | Cash or cash equivalent | JORNAY PM Drug, CENTRAL NERVOUS SYSTEM STIMULANT | 2023 | |
| 2023-02-21 | Corium, LLC | $8 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2023 | |
| 2023-02-08 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-01-31 | Eli Lilly and Company | $147 | Research payment | In-kind items and services | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEK | 2023 | |
| 2023-01-25 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2023-01-24 | IRONSHORE PHARMACEUTICALS INC. | $15 | Food and Beverage | Cash or cash equivalent | JORNAY PM Drug, CENTRAL NERVOUS SYSTEM STIMULANT | 2023 | |
| 2023-01-24 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2023 | |
| 2023-01-21 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2023 | |
| 2023-01-12 | SANOFI PASTEUR INC. | $19 | Food and Beverage | In-kind items and services | VAXELIS Biological, Vaccines | 2023 | |
| 2023-01-10 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2023 | |
| 2023-01-05 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2023 | |
| 2022-12-20 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-12-16 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $24 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-12-14 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-12-13 | Novo Nordisk Inc | $8 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-12-10 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $24 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-12-08 | AstraZeneca Pharmaceuticals LP | $11 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-11-29 | IRONSHORE PHARMACEUTICALS INC. | $12 | Food and Beverage | In-kind items and services | JORNAY PM Drug, Central Nervous Stimulant ADHD | 2022 | |
| 2022-11-28 | Lilly USA, LLC | $10 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2022 | |
| 2022-11-15 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-11-07 | Cranial Technologies, Inc | $14 | Food and Beverage | Cash or cash equivalent | Doc Band Device, Cranial Orthotic | 2022 | |
| 2022-10-26 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2022 | |
| 2022-10-13 | Novo Nordisk Inc | $10 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-10-13 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-10-11 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-10-03 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-09-30 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $16 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-09-27 | Supernus Pharmaceuticals, Inc. | $19 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2022 | |
| 2022-09-26 | Eli Lilly and Company | $5,223 | Research payment | Cash or cash equivalent | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEP | 2022 | |
| 2022-09-22 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-09-22 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-09-21 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-09-21 | ABBVIE INC. | $0 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-09-19 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2022 | |
| 2022-09-16 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-09-11 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-09-07 | IRONSHORE PHARMACEUTICALS INC. | $12 | Food and Beverage | In-kind items and services | JORNAY PM Drug, Central Nervous Stimulant ADHD | 2022 | |
| 2022-08-29 | Cranial Technologies, Inc | $12 | Food and Beverage | Cash or cash equivalent | Doc Band Device, Cranial Orthotic | 2022 | |
| 2022-08-26 | Ultragenyx Pharmaceutical Inc. | $18 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-08-23 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-08-15 | Eli Lilly and Company | $70,079 | Research payment | Cash or cash equivalent | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A W | 2022 | |
| 2022-08-15 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-08-10 | Novo Nordisk Inc | $18 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-08-05 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $11 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-08-03 | Corium, LLC | $14 | Food and Beverage | In-kind items and services | AZSTARYS Drug, CNS Stimulant for ADHD | 2022 | |
| 2022-08-02 | PFIZER INC. | $14 | Food and Beverage | In-kind items and services | PREVNAR 13 Biological, VACCINES | 2022 | |
| 2022-08-01 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-07-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19 | Food and Beverage | In-kind items and services | JARDIANCE Drug, DIABETES | 2022 | |
| 2022-07-14 | Novo Nordisk Inc | $9 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-07-12 | Lilly USA, LLC | $15 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-07-12 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-07-02 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $26 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-06-20 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | MOUNJARO Drug, Diabetes | 2022 | |
| 2022-06-14 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-06-10 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-05-31 | Eli Lilly and Company | $16,580 | Research payment | In-kind items and services | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A W | 2022 | |
| 2022-05-24 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2022 | |
| 2022-05-16 | Lilly USA, LLC | $13 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-05-10 | Novo Nordisk Inc | $22 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2022 | |
| 2022-05-09 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-05-06 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $33 | Food and Beverage | In-kind items and services | NURTEC ODT Drug, PRIMARY CARE | 2022 | |
| 2022-04-26 | Supernus Pharmaceuticals, Inc. | $12 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2022 | |
| 2022-04-14 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-04-12 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | 2022 | ||
| 2022-04-11 | Lilly USA, LLC | $17 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-04-06 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-04-06 | Abbott Laboratories | $19 | Food and Beverage | In-kind items and services | FREESTYLE LIBRE Device, Diabetes Care | 2022 | |
| 2022-03-22 | Supernus Pharmaceuticals, Inc. | $13 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2022 | |
| 2022-03-15 | Novo Nordisk Inc | $19 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-03-15 | Novo Nordisk Inc | $0 | Food and Beverage | In-kind items and services | Saxenda Drug, Obesity | 2022 | |
| 2022-03-14 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-03-10 | Novo Nordisk Inc | $14 | Food and Beverage | In-kind items and services | Rybelsus Drug, Diabetes | 2022 | |
| 2022-03-09 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-03-07 | Lilly USA, LLC | $12 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2022 | |
| 2022-03-03 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2022 | |
| 2022-03-01 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2022-02-24 | Ultragenyx Pharmaceutical Inc. | $20 | Food and Beverage | In-kind items and services | Crysvita Drug, XLH Metabolic Bone Disorder | 2022 | |
| 2022-02-18 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2022 | |
| 2022-02-14 | Supernus Pharmaceuticals, Inc. | $14 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2022 | |
| 2022-02-02 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2022 | |
| 2022-01-31 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2022 | |
| 2021-12-14 | Supernus Pharmaceuticals, Inc. | $11 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2021 | |
| 2021-12-07 | Takeda Pharmaceuticals U.S.A., Inc. | $11 | Food and Beverage | In-kind items and services | VYVANSE Drug, NEUROSCIENCE | 2021 | |
| 2021-12-06 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-12-03 | Corium, LLC | $18 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2021 | |
| 2021-12-01 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-11-29 | PFIZER INC. | $13 | Food and Beverage | In-kind items and services | PREVNAR 20 Biological, VACCINES | 2021 | |
| 2021-11-23 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | PEDIARIX Biological, VACCINES | 2021 | |
| 2021-11-18 | AstraZeneca Pharmaceuticals LP | $13 | Food and Beverage | In-kind items and services | FLUMIST QUADRIVALENT Biological, Respiratory | 2021 | |
| 2021-11-18 | Medtronic, Inc. | $12 | Food and Beverage | In-kind items and services | InPen Device, Continuous Glucose Monitoring | 2021 | |
| 2021-11-15 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | LUPRON DEPOT Drug, ENDOCRINOLOGY | 2021 | |
| 2021-11-11 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-11-05 | Lilly USA, LLC | $11 | Food and Beverage | In-kind items and services | EMGALITY Drug, Neuroscience | 2021 | |
| 2021-10-28 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | QULIPTA Drug, NEUROSCIENCE | 2021 | |
| 2021-10-27 | Supernus Pharmaceuticals, Inc. | $16 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2021 | |
| 2021-10-26 | Bayer Healthcare Pharmaceuticals Inc. | $12 | Food and Beverage | In-kind items and services | Kerendia Drug, Cardio-renal | 2021 | |
| 2021-10-22 | Corium, LLC | $21 | Food and Beverage | In-kind items and services | Azstarys Drug, CNS Stimulant for ADHD | 2021 | |
| 2021-09-28 | Ultragenyx Pharmaceutical Inc. | $18 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-09-17 | Teva Pharmaceuticals USA, Inc. | $12 | Food and Beverage | In-kind items and services | AirDuo Digihaler Drug, Respiratory | 2021 | |
| 2021-09-14 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-09-09 | GlaxoSmithKline, LLC. | $130 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2021 | |
| 2021-09-06 | Takeda Pharmaceuticals U.S.A., Inc. | $16 | Food and Beverage | In-kind items and services | VYVANSE Drug, NEUROSCIENCE | 2021 | |
| 2021-09-02 | Novo Nordisk Inc | $15 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-09-01 | GlaxoSmithKline, LLC. | $14 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-08-30 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-08-30 | ABBVIE INC. | $0 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-08-17 | Supernus Pharmaceuticals, Inc. | $12 | Food and Beverage | Cash or cash equivalent | QELBREE Drug, PSYCHOLOGY | 2021 | |
| 2021-08-03 | Takeda Pharmaceuticals U.S.A., Inc. | $15 | Food and Beverage | In-kind items and services | VYVANSE Drug, NEUROSCIENCE | 2021 | |
| 2021-07-28 | Siemens Medical Solutions USA, Inc. | $29 | Food and Beverage | In-kind items and services | RAPIDPoint 400/405/500 Wash/Waste Cartridge Device, DX - Diagnostics incl. all products and services | 2021 | |
| 2021-07-20 | Merck Sharp & Dohme LLC | $11 | Food and Beverage | In-kind items and services | GARDASIL 9 Biological, VACCINE | 2021 | |
| 2021-07-13 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-07-03 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | COLOGUARD DNA CAPTURE REAGENTS Device, GASTROINTESTINAL | 2021 | |
| 2021-07-01 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-06-21 | PFIZER INC. | $12 | Food and Beverage | In-kind items and services | COLOGUARD DNA CAPTURE REAGENTS Device, GASTROINTESTINAL | 2021 | |
| 2021-06-17 | GlaxoSmithKline, LLC. | $125 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-06-16 | GlaxoSmithKline, LLC. | $10 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-05-31 | Takeda Pharmaceuticals U.S.A., Inc. | $14 | Food and Beverage | In-kind items and services | VYVANSE Drug, NEUROSCIENCE | 2021 | |
| 2021-05-28 | ABBVIE INC. | $4 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-05-24 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | 2021 | |
| 2021-05-05 | Novo Nordisk Inc | $16 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-05-03 | GlaxoSmithKline, LLC. | $7 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-04-28 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-04-26 | SANOFI PASTEUR INC. | $14 | Food and Beverage | In-kind items and services | MENQUADFI Biological, Vaccines | 2021 | |
| 2021-04-22 | Teva Pharmaceuticals USA, Inc. | $11 | Food and Beverage | In-kind items and services | AirDuo Digihaler Drug, Respiratory | 2021 | |
| 2021-04-15 | Lilly USA, LLC | $14 | Food and Beverage | In-kind items and services | TRULICITY Drug, Diabetes | 2021 | |
| 2021-04-12 | Takeda Pharmaceuticals U.S.A., Inc. | $16 | Food and Beverage | In-kind items and services | TRINTELLIX Drug, NEUROSCIENCE | 2021 | |
| 2021-04-01 | Novo Nordisk Inc | $11 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2021 | |
| 2021-03-24 | ABBVIE INC. | $27 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2021 | |
| 2021-03-23 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2021-03-12 | ABBVIE INC. | $10 | Food and Beverage | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 2021 | |
| 2021-03-03 | Cranial Technologies, Inc | $15 | Food and Beverage | Cash or cash equivalent | Doc Band Device, Cranial Orthotic | 2021 | |
| 2021-02-08 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-02-04 | GlaxoSmithKline, LLC. | $11 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2021 | |
| 2021-02-02 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | CREON Drug, ENDOCRINOLOGY | 2021 | |
| 2021-01-26 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2021 | |
| 2021-01-13 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2021 | |
| 2020-12-08 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2020 | |
| 2020-11-13 | GlaxoSmithKline, LLC. | $12 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2020 | |
| 2020-11-04 | Novo Nordisk Inc | $12 | Food and Beverage | In-kind items and services | Ozempic Drug, Diabetes | 2020 | |
| 2020-10-20 | GlaxoSmithKline, LLC. | $15 | Food and Beverage | In-kind items and services | BEXSERO Biological, VACCINES | 2020 | |
| 2020-10-16 | Medtronic Vascular, Inc. | $16 | Food and Beverage | In-kind items and services | TurboHawk Device, Directional Atherectomy Devices | 2020 | |
| 2020-10-15 | Novo Nordisk Inc | $13 | Food and Beverage | In-kind items and services | Tresiba Drug, Diabetes | 2020 |
The latest 200 records of 301.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-03-19 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $361 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2025 |
| 2025-01-13 | AstraZeneca UK Limited | QUALMEDICA RESEARCH | $34,850 | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre | 2025 |
| 2024-08-12 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $7,278 | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A W | 2024 |
| 2024-03-28 | Acrotech Biopharma Inc. | QUALMEDICA RESEARCH LLC | $17,887 | 246-13651-302 | 2024 |
| 2024-01-31 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $98 | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A W | 2024 |
| 2024-01-31 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $1,525 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-25 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $533 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2024 |
| 2024-01-10 | AstraZeneca UK Limited | QUALMEDICA RESEARCH | $178,728 | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre | 2024 |
| 2024-01-09 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $33,559 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2024 |
| 2024-01-02 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $62,814 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION | 2024 |
| 2023-12-20 | Acrotech Biopharma Inc. | QUALMEDICA RESEARCH LLC | $25,423 | 246-13651-302 | 2023 |
| 2023-11-09 | Acrotech Biopharma Inc. | QUALMEDICA RESEARCH LLC | $23,360 | 246-13651-302 | 2023 |
| 2023-10-20 | AstraZeneca UK Limited | QUALMEDICA RESEARCH | $150,238 | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre | 2023 |
| 2023-07-18 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $1,430 | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEK | 2023 |
| 2023-05-26 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $16,975 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-05-23 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $127,861 | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF | 2023 |
| 2023-05-11 | Acrotech Biopharma Inc. | QUALMEDICA RESEARCH LLC | $15,998 | 246-13651-302 | 2023 |
| 2023-04-06 | Acrotech Biopharma Inc. | QUALMEDICA RESEARCH LLC | $2,000 | 246-13651-302 | 2023 |
| 2023-04-04 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $4,250 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2023 |
| 2023-03-21 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $81 | A RANDOMIZED OPEN-LABEL PARALLEL-GROUP TWO-ARM PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATID | 2023 |
| 2023-03-10 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $1,435 | A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O | 2023 |
| 2023-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $1,000 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2023 |
| 2023-03-08 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $1,000 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2023 |
| 2023-03-07 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $1,509 | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF | 2023 |
| 2023-02-16 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $696 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2023 |
| 2023-01-26 | Acrotech Biopharma Inc. | QUALMEDICA RESEARCH LLC | $3,873 | 246-13651-302 | 2023 |
| 2023-01-10 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $28,472 | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEK | 2023 |
| 2022-08-08 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $1,724 | A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEP | 2022 |
| 2022-05-18 | Eli Lilly and Company | QUALMEDICA RESEARCH LLC | $1,850 | A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A W | 2022 |
| 2022-04-19 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $2,089 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2022 |
| 2021-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $1,250 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2021 |
| 2021-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $1,857 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2021 |
| 2021-12-16 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $2,322 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2021 |
| 2021-08-26 | Takeda Pharmaceuticals U.S.A., Inc. | QUALMEDICA RESEARCH LLC | $4,500 | A PHASE 4, MULTICENTER, 2-PART STUDY COMPOSED OF A 1-YEAR RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Bowling Green, KY, county Warren County, KY, state Kentucky; placed by its city name.
| Measure | Place (city or town) Bowling Green, KY | County Warren County, KY | State Kentucky |
|---|---|---|---|
| Population B01003 | 75,388 | 140,918 | 4,534,824 |
| Population, 2020 census P1 | 72,294 | 134,554 | 4,505,836 |
| Median age B01002 | 28.7 | 33.3 | 39.1 |
| Under 18 B01001 | 22.7% | 23.7% | 22.6% |
| 65 and over B01001 | 11.4% | 13.2% | 17.3% |
| Households B11001 | 30,633 | 55,643 | 1,814,469 |
| Foreign born B05002 | 15.0% | 10.4% | 4.7% |
| Median household income B19013 | $48,873 | $65,794 | $63,726 |
| Median family income B19113 | $68,257 | $84,378 | $81,505 |
| Per capita income B19301 | $28,971 | $35,497 | $35,821 |
| Poverty rate B17001 | 25.6% | 17.0% | 16.1% |
| Unemployment rate B23025 | 4.9% | 4.4% | 4.9% |
| Civilian labor force B23025 | 38,770 | 73,294 | 2,152,038 |
| Mean commute (minutes) B08013 | 17.8 | 20.3 | 24.0 |
| Bachelor's degree or higher B15003 | 31.2% | 32.3% | 27.6% |
| Housing units B25001 | 33,481 | 59,868 | 2,023,116 |
| Owner-occupied B25003 | 36.6% | 55.6% | 68.3% |
| Renters B25003 | 63.4% | 44.4% | 31.7% |
| Median home value B25077 | $241,900 | $258,000 | $205,600 |
| Median gross rent B25064 | $998 | $1,002 | $967 |
| White, not Hispanic B03002 | 62.1% | 73.8% | 81.5% |
| Black B03002 | 14.1% | 9.1% | 7.6% |
| Hispanic or Latino B03002 | 10.6% | 7.1% | 5.0% |
| Asian B03002 | 7.7% | 5.0% | 1.6% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Economy now FRED unemployment 4.7% in Sep 2026 (4.5% a year earlier); per capita personal income $60,835 in 2025, up 29% in five years (+3.9% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Bowling Green, KY.
Comments